Gel cuts inflammation and pain

Article

Loteprednol etabonate gel 0.5% is efficacious and safe for treating postoperative inflammation and pain caused by cataract surgery, claims a recent report.

Loteprednol etabonate gel 0.5% is efficacious and safe for treating postoperative inflammation and pain caused by cataract surgery, claims a recent report.

Dr Rajesh K. Raipal et al., See Clearly Vision Group, McLean, Virginia, USA, completed a prospective double-masked parallel-group study on 406 patients who underwent cataract surgery. Patients with anterior chamber cell (ACC) grade two or higher after surgery were randomized to receive loteprednol etabonate 0.5% gel or vehicle four times daily for 14 days.

Primary outcome measures included proportion of patients with complete resolution of ACC and no pain on postoperative day eight. The safety measures included adverse events, intraocular pressure (IOP), visual acuity, biomicroscopy and funduscopy findings and tolerability (ocular symptoms and drop comfort).

On day eight of the follow-up period 30.5% of the patients in the loteprednol group and 16.3% in the vehicle group had complete resolution of ACC, but the remainder had grade 0 pain.

Loteprednol etabonate was favoured as a method for complete resolution of ACC and grade 0 pain. One patient in each group experienced a significant increase in IOP but overall 85% of patients reported no discomfort on drop instillation.

The abstract was published in the latest edition of the Journal of Cataract and Refractive Surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.